TAMPA, Fla., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL® (bupivacaine liposome injectable suspension) and iovera° for the month of January 2022. EXPAREL net product sales were $36.3 million, compared with $34.9 million for January 2021. EXPAREL average daily sales for the month of January 2022 were 104 percent of January 2021. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. The number of EXPAREL selling days were 20 in both January 2022 and January 2021. Net product sales of iovera° were $1.1 million for the month of January 2022, compared with $1.1 million for January 2021.
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
